The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma

References

• Ducimetière F, Lurkin A, Ranchère-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6(8):e20294.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5–29.
   PubMed Web of Science ®Google Scholar
• Fletcher CDM, Bridge JA, Hogendoorn PCW, et al., editors. WHO classification of tumours of soft tissue and bone. Lyon: IARC Press; 2013.
   Google Scholar
• ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25Suppl 3:iii21–6.
   Web of Science ®Google Scholar
• Callegaro D, Fiore M, Gronchi A. Personalizing surgical margins in retroperitoneal sarcomas. Expert Rev Anticancer Ther. 2015 May;15(5):553–567.
   PubMed Web of Science ®Google Scholar
• Dickie CI, Haas R, O’Sullivan B. Adjuvant radiation for soft tissue sarcomas. Am Soc Clin Oncol Educ Book. 2015;35:e634–42.
   Google Scholar
• A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma (RPS) - STRASS. Available from: https://clinicaltrials.gov/ct2/show/NCT01344018.
   Google Scholar
• Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008 Aug 1;113(3):573–581.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Ouali M, Leahy MG, et al. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014 Dec;25(12):2425–2432.
   PubMed Web of Science ®Google Scholar
• Blay JY, Van Glabbeke M, Verweij J, et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer. 2003 Jan;39(1):64–69.
   PubMed Web of Science ®Google Scholar
• Karavasilis V, Seddon BM, Ashley S, et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer. 2008 Apr 1;112(7):1585–1591.
   PubMed Web of Science ®Google Scholar
• Gronchi A, Miceli R, Colombo C, et al. Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. Ann Oncol. 2011 Jul;22(7):1675–1681.
   PubMed Web of Science ®Google Scholar
• van der Graaf WT, Blay JY, Chawla SP, et al.; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879–1886.
   PubMed Web of Science ®Google Scholar
• Judson I, Verweij J, Gelderblom H, et al.; European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014 Apr;15(4):415–423.
   PubMed Web of Science ®Google Scholar
• Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995 Jul;13(7):1537–1545.
   PubMed Web of Science ®Google Scholar
• Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993 Jul;11(7):1269–1275.
   PubMed Web of Science ®Google Scholar
• Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993 Jul;11(7):1276–1285.
   PubMed Web of Science ®Google Scholar
• Worden FP, Taylor JM, Biermann JS, et al. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol. 2005 Jan 1;23(1):105–112.
   PubMed Web of Science ®Google Scholar
• Fayette J, Penel N, Chevreau C, et al. Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. Invest New Drugs. 2009 Oct;27(5):482–489.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000 Jul;18(14):2676–2684.
   PubMed Web of Science ®Google Scholar
• Maurel J, López-Pousa A, De Las Peñas R, et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. J Clin Oncol. 2009 Apr 10;27(11):1893–1898.
   PubMed Web of Science ®Google Scholar
• Bui-Nguyen B, Ray-Coquard I, Chevreau C, et al.; GSF-GETO French Sarcoma Group. High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. Ann Oncol. 2012 Mar;23(3):777–784.
   PubMed Web of Science ®Google Scholar
• Verma S, Younus J, Stys-Norman D, et al.; Members of the Sarcoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev. 2008 Jun;34(4):339–347.
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 1999;17(1):150–157.
   PubMed Web of Science ®Google Scholar
• Wagner MJ, Amodu LI, Duh MS, et al. A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments. BMC Cancer. 2015 Mar 25;15:175.
   PubMed Web of Science ®Google Scholar
• Larsen AK, Galmarini CM, D’Incalci M. Unique features of trabectedin mechanism of action. Cancer Chemother Pharmacol. 2015. published online 14 December 2015. doi:10.1007/s00280-015-2918-1.
   PubMedGoogle Scholar
• Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013 Feb 11;23(2):249–262.
   PubMed Web of Science ®Google Scholar
• Allavena P, Germano G, Belgiovine C, et al. Trabectedin: A drug from the sea that strikes tumor-associated macrophages. Oncoimmunology. 2013 Jun 1;2(6):e24614.
   PubMed Web of Science ®Google Scholar
• Puchalski TA, Ryan DP, Garcia-Carbonero R, et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol. 2002 Oct;50(4):309–319.
   PubMed Web of Science ®Google Scholar
• Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res. 2001 Feb;7(2):231–242.
   PubMed Web of Science ®Google Scholar
• Twelves C, Hoekman K, Bowman A, et al. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer. 2003 Sep;39(13):1842–1851.
   PubMed Web of Science ®Google Scholar
• Villalona-Calero MA, Eckhardt SG, Weiss G, et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res. 2002 Jan;8(1):75–85.
   PubMed Web of Science ®Google Scholar
• Taamma A, Misset JL, Riofrio M, et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol. 2001 Mar 1;19(5):1256–1265.
   PubMed Web of Science ®Google Scholar
• Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004 Mar 1;22(5):890–899.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004 Apr 15;22(8):1480–1490.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005 Jan 20;23(3):576–584.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Chawla SP, Von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009 Sep 1;27(25):4188–4196.
   PubMed Web of Science ®Google Scholar
• Samuels BL, Chawla S, Patel S, et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol. 2013 Jun;24(6):1703–1709.
   PubMed Web of Science ®Google Scholar
• Blay JY, Italiano A, Ray-Coquard I, et al. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer. 2013 Feb 6;13:64.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Judson I, Maki R, et al. Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. Br J Cancer. 2013 Oct 1;109(7):1717–1724.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2015;4734. published online 14 September 2015. doi:10.1200/JCO.2015.62.
   Google Scholar
• Patel S, Von Mehren M, Reed D, et al. Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS), M. Presented at ECCO 18/ESMO 40; Sep 25–29; Vienna, Austria. Abstract number 3403.
   Google Scholar
• Jones RL, Fisher C, Al-Muderis O, et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005 Dec;41(18):2853–2860.
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee J, Yi SY, et al. Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy. BMC Cancer. 2009 Jun 9;1:205.
   Web of Science ®Google Scholar
• Fiore M, Grosso F, Lo Vullo S, et al. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2007 Jun 15;109(12):2522–2531.
   PubMed Web of Science ®Google Scholar
• Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8(7):595–602.
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Collini P, Messina A, et al. High-grade soft-tissue sarcomas: tumor response assessment–pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology. 2009 May;251(2):447–456.
   PubMed Web of Science ®Google Scholar
• Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol. 2009 Aug;20(8):1439–1444.
   PubMed Web of Science ®Google Scholar
• Crozat A, Aman P, Mandahl N, et al. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. 1993 Jun 17;363(6430):640–644.
   PubMed Web of Science ®Google Scholar
• Dal Cin P, Sciot R, Panagopoulos I, et al. Additional evidence of a variant translocation t(12;22) with EWS/CHOP fusion in myxoid liposarcoma: clinicopathological features. J Pathol. 1997 Aug;182(4):437–441.
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Simone M, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010 Mar 15;70(6):2235–2244.
   PubMed Web of Science ®Google Scholar
• Charytonowicz E, Terry M, Coakley K, et al. PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest. 2012 Mar;122(3):886–898.
   PubMed Web of Science ®Google Scholar
• Dossi R, Frapolli R, Di Giandomenico S, et al. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. Int J Cancer. 2015 Feb 1;136(3):721–729.
   PubMed Web of Science ®Google Scholar
• Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009 Feb;8(2):449–457.
   PubMed Web of Science ®Google Scholar
• Di Giandomenico S, Frapolli R, Bello E, et al. Mode of action of trabectedin in myxoid liposarcomas. Oncogene. 2014 Oct 30;33(44):5201–5210.
   PubMed Web of Science ®Google Scholar
• Gronchi A, Bui BN, Bonvalot S, et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol. 2012 Mar;23(3):771–776.
   PubMed Web of Science ®Google Scholar
• Localized high-risk soft tissue sarcomas of the extremities and trunk wall in adults: an integrating approach comprising standard vs histotype-tailored neoadjuvant chemotherapy. Available from: https://clinicaltrials.gov/ct2/show/NCT01710176.
   Google Scholar
• Le Cesne A, Ray-Coquard I, Duffaud F, et al.; French Sarcoma Group. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. Eur J Cancer. 2015 Apr;51(6):742–750.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay JY, Domont J, et al. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Lancet Oncol. 2015;16(3):312–319.
   PubMed Web of Science ®Google Scholar
• Yondelis® summary of product characteristics. Available from: www.ema.europa.eu/docs/en_GB.
   Google Scholar
• Grosso F, D’Incalci M, Cartoafa M, et al. A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin. Cancer Chemother Pharmacol. 2012 Jun;69(6):1557–1565.
   PubMed Web of Science ®Google Scholar
• van Oosterom AT, Mouridsen HT, Nielsen OS, et al.; EORTC Soft Tissue and Bone Sarcoma Group. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer. 2002 Dec;38(18):2397–2406.
   PubMed Web of Science ®Google Scholar
• Sanfilippo R, Bertulli R, Marrari A, et al. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. Clin Sarcoma Res. 2014 Nov 22;4(1):16.
   PubMedGoogle Scholar
• Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007 Jul 1;25(19):2755–2763.
   PubMed Web of Science ®Google Scholar
• Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist. 2012;17(9):1213–1220.
   PubMed Web of Science ®Google Scholar
• García-Del-Muro X, López-Pousa A, Maurel J, et al.; Spanish Group for Research on Sarcomas. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011 Jun 20;29(18):2528–2533.
   PubMed Web of Science ®Google Scholar
• Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016. published online 10 February 2016. doi:10.1016/S0140-6736(15)01283-0.
   PubMed Web of Science ®Google Scholar
• Leahy M, Garcia Del Muro X, Reichardt P, et al.; SABINE Investigators. Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study. Ann Oncol. 2012 Oct;23(10):2763–2770.
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Verderio P, Messina A, et al. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer. 2012 Dec 1;118(23):5857–5866.
   PubMed Web of Science ®Google Scholar
• Hollebecque A, Adenis A, Taieb S, et al. Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients. Invest New Drugs. 2010 Aug;28(4):529–530.
   PubMed Web of Science ®Google Scholar
• Bui-Nguyen B, Butrynski JE, Penel N, et al.; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC/STBSG) and the Sarcoma Alliance for Research through Collaboration (SARC). A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. Eur J Cancer. 2015 Jul;51(10):1312–1320.
   PubMed Web of Science ®Google Scholar
• Blay J-Y, Leahy MG, Nguyen BB, et al. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer. 2014 Apr;50(6):1137–1147.
   PubMed Web of Science ®Google Scholar
• Grohar PJ, Segars LE, Yeung C, et al. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res. 2014 Mar 1;20(5):1190–1203.
   PubMed Web of Science ®Google Scholar
• D’Incalci M, Colombo T, Ubezio P, et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer. 2003 Sep;39(13):1920–1926.
   PubMed Web of Science ®Google Scholar
• Sessa C, Cresta S, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur J Cancer. 2009 Aug;45(12):2116–2122.
   PubMed Web of Science ®Google Scholar
• Sessa C, Del Conte G, Christinat A, et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors. Invest New Drugs. 2013 Oct;31(5):1236–1243.
   PubMed Web of Science ®Google Scholar
• Messersmith WA, Jimeno A, Ettinger D, et al. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Dec;63(1):181–188.
   PubMed Web of Science ®Google Scholar
• Kasper B, Reichardt P, Pink D, et al. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG). Mar Drugs. 2015 Jan 13;13(1):379–388.
   PubMed Web of Science ®Google Scholar
• Von Mehren M, Schilder RJ, Cheng JD, et al. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol. 2008 Oct;19(10):1802–1809.
   PubMed Web of Science ®Google Scholar
• Blay JY, Von Mehren M, Samuels BL, et al. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res. 2008 Oct 15;14(20):6656–6662.
   PubMed Web of Science ®Google Scholar
• Sessa C, Perotti A, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer. 2009 May;45(7):1153–1161.
   PubMed Web of Science ®Google Scholar
• Pautier P, Floquet A, Chevreau C, et al.; French Sarcoma Group. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2015 Apr;16(4):457–464.
   PubMed Web of Science ®Google Scholar
• A phase Ib study on the combination of trabectedin and olaparib in unresectable advanced/metastatic sarcomas after failure of standard therapies. Available from: https://clinicaltrials.gov/ct2/show/NCT02398058.
   Google Scholar